Collaborations with antibodies for type 2 diabetes
Our type 2 diabetes candidates comprise collaboration where two top pharma manages the development of antibodies identified with our Abiprot™ platform.
About type 2 diabetes
The condition is a chronic endocrine disorder symbolized by high blood sugar (hyper-glycemia) due to diminished effect of insulin, the hormone responsible for regulating sugar levels in the blood. Type 2 diabetes is considered insulin independent as the issue lies in desensitization of cells to the hormone, which means that an increased level of the hormone did not improve the condition. It is estimated that around 380 million people globally has type 2 diabetes, which is the majority of those affected by diabetes. According to an estimation from WHO, more than 1.5 million people dies annually as direct consequence of diabetes.1
American Diabetes Association recently published a report with the estimation that the total cost of patients diagnosed with diabetes in 2017 was 327 billion USD. This included 237 billion USD in direct medical costs and 90 billion USD in reduced productivity.2 While risk factors of type 2 diabetes include genetic predispositions and obesity, nearly 90% of patients are treated with pharmacological means rather than lifestyle adjustments alone.3 The, therefore, large therapeutic market of type 2 diabetes has been estimated to amount to more than 26 billion USD annually in EU5 (France, Germany, Italy, Spain and UK), Japan and U.S. combined.4
1. World Health Organization. Global report on diabetes. World Health Organization, 2016. 2. American Diabetes Association. ”Economic Costs of Diabetes in the US in 2017.” Diabetes care 41.5 (2018): 917. 3. Datamonitor Healthcare’s proprietary diabetes survey, May 2016. 4. Datamonitor Healthcare’s Forecast: Type 2 Diabetes 2016–25